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by macrophages? Second, macrophage-
produced factors are also likely to acti-
vate keratinocytes or other cells in the
skin to release factors that promote
melanocyte proliferation and migration.
An in vitro co-culturing system, includ-
ing melanocytes, keratinocytes, and
macrophages, followed by in vivo vali-
dation, may identify signaling pathways
that are directly and/or indirectly acti-
vated by UVR exposure in melanocytes.
Third, even though IL-17 has a role in
the increase of melanocytes and macro-
phages on UVB exposure, the effect
appears modest, suggesting that other
factors also confer UVB-induced macro-
phage recruitment. Future studies
should be conducted to identify which
population of macrophages contributes
to UVB-induced melanocyte responses.
In Zaidi et al’s study (2011), it appears
that most SIMs are CCR2-positive
macrophages. However, CCR2-negative
Ly6clowMHChigh macrophages confer
melanocyte responses in Handoko
et al. (2013) study, even though both
groups have used CCR2-knockout mice
to address this question. Finally, it will
be interesting to determine whether
macrophages have a role in other skin
responses induced by UVB exposure.
For example, macrophages produce
many growth factors, extracellular
matrix (ECM) proteins, and cytokines
that might also critically affect immuno-
suppressive functions and differentiation
of melanocyte stem cells and progenitor
cells seen in UVB-treated mice.
Despite many challenges regarding
how macrophages contribute to UVB-
mediated melanoma development, both
Handoko et al. (2013) and Zaidi et al
provide strong evidence that macro-
phages are involved in the initiation of
melanoma; hence, targeting macro-
phages or their products might be used
as a novel approach to prevent mela-
noma development and progression.
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Do Not Underestimate Nucleotide
Excision Repair: It Predicts Not Only
Melanoma Risk but Also Survival
Outcome
Steffen Emmert1 and Kenneth H. Kraemer2
Nucleotide excision repair (NER) removes UV-induced DNA damage and other
bulky DNA lesions, thereby maintaining genomic integrity. Dr Qingyi Wei’s group
demonstrated over the last decade that NER fidelity and single-nucleotide
polymorphisms (SNPs) in NER genes constitute melanoma risk biomarkers. In
this issue, Li et al. provide evidence that SNPs in NER genes may also predict
melanoma survival.
Journal of Investigative Dermatology (2013) 133, 1713–1717. doi:10.1038/jid.2013.72
The melanoma problem
Skin cancer is the most frequent form
of cancer in Caucasians. Cutaneous
melanoma is the most aggressive form
of skin cancer and its frequency is
increasing rapidly. In the United States,
there were approximately 76,000 new
melanoma cases and 56,000 melanoma
See related article on pg 1813
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in situ cases in 2012. Melanoma mor-
tality increased in the United States at
an annual rate of 1.5% from 1950 to
2005. More than 8,000 deaths from
melanoma are estimated per year.
In the clinical setting, relatively crude
melanoma risk factors are applied
today, including family history of
melanoma, age, gender, amount of
sunlight exposure (particularly intense
intermittent exposure), sensitivity to sun-
burning, freckling, fair hair, eye and
skin color, and number and size of nevi
(Blankenburg et al., 2005; see also the
NCI melanoma risk assessment tool
http://www.cancer.gov/melanomarisktool).
Discoveries reported in recent years
constitute breakthroughs in the funda-
mental understanding of the molecular
basis of melanoma and have resulted in
development of novel therapeutic
targets including small molecules
(BRAF inhibitors) and immunotherapies
(CTLA-4 antibodies). Many of the
molecular pathways to melanoma
appear to depend on exposure to UV.
UV and melanoma
The physiologically relevant UV spec-
trum reaching the human skin can be
divided into UVA (400–320 nm) and
UVB (320–280 nm). Despite constituting
only 5% of the solar spectrum, UVB is
considered mainly responsible for skin
carcinogenesis. UVB forms cyclobutane
pyrimidine dimers (CPDs), pyrimidine-
6,4-pyrimidone photoproducts (6–4 PP),
and some minor photoproducts through
direct energy transfer to the DNA mole-
cule. If not repaired, these DNA lesions
may lead to UV ‘‘fingerprint’’ mutations
at adjacent pyrimidines. In contrast to
UVB, UVA penetrates deeper into the
skin reaching the dermis and acts indir-
ectly by producing reactive oxygen spe-
cies leading to oxidative DNA damage.
However, UVA can also generate CPD
lesions. Thus, both UVB and UVA
appear to have a role in melanoma
induction (von Thaler et al., 2010).
The prognostic markers currently used
in the clinic indirectly reflect the mole-
cular biology that drives melanoma
progression. Thus, the markers included
in the latest AJCC melanoma staging
system are surrogates of key biological
events (Spatz et al., 2010). Gene
expression signatures suggest that the
‘‘primary melanoma thickness’’ marker
may represent a quantitative surrogate
of the total multifactorial biological
machinery driving melanoma progress-
ion and invasion. The biological signifi-
cance of ‘‘primary melanoma ulcera-
tion’’ may indicate a special tumor
attribute or directly indicate tumor cell
dissemination, for example, by modify-
ing the local environment. The male
gender effect on adverse melanoma out-
come is clearly established (adjusted
relative excess risk of death from
melanoma is 1.85). One explanation,
supported by the microarray data, could
be the existence of metastasis-suppres-
sor genes located on the X chromosome.
Genes involved in DNA replication, as
well as DNA repair, may represent the
molecular basis of the ‘‘mitotic activity’’
marker. Aggressively growing melano-
mas need fast replication machinery and
need to repair DNA damage effectively.
The fact that cutaneous melanomas are
continuously exposed to UV even after
tumor formation highlights the rationale
for nucleotide excision repair (NER) as
an important molecular pathway for
tumor maintenance.
Xeroderma pigmentosum (XP) as a
melanoma model disease
The fact that the NER pathway (Figure 1)
has a role in melanoma prevention is
evident from studies of the rare auto-
somal recessive disease, XP (Wang
et al., 2009; Bradford et al., 2011;
DiGiovanna and Kraemer, 2012). XP
patients have defective NER and
develop freckle-like lesions in the sun-
exposed skin. XP patients under 20
years of age have a more than 1,000-
fold increased melanoma risk. Intere-
stingly, the hallmark acute burning on
minimal sun exposure may not be
present in 30–40% of all XP patients,
mainly in those patients with defects in
the XPC or polymerase eta genes. The
median age at diagnosis of the first
cutaneous melanoma was 22 years in
the XP patients compared with 50–55
years in the normal Caucasian popula-
tion. The median age of death due to
skin cancer was 37 years in XP
(Bradford et al., 2011). It is noteworthy
that the site distribution of cutaneous
melanomas was similar in XP patients
and normal Caucasians.
Seven different NER genes that correct
seven distinct genetic XP complementa-
tion groups (XP-A to XP-G) have been
identified (DiGiovanna and Kraemer,
2012). However, the NER pathway
consists of at least 23 genes/proteins
that act in a well-defined sequential
manner to repair bulky and UV-
induced DNA damage (Figure 1). Sev-
eral steps constitute the NER process.
First, the DNA lesion is recognized by
the XPE(DDB2) and XPC gene products,
then the strand containing the lesion is
unwound by XPB(ERCC3) and
XPD(ERCC2) gene product helicases
and incised on both sides of the lesion
by XPG(ERCC5) and XPF(ERCC4) gene
product endonucleases with damaged-
strand displacement. Finally, the result-
ing gap is filled by DNA polymerases
using the opposite strand as a template,
followed by strand ligation. The two
subpathways of NER, global genome
repair (GGR) and transcription-coupled
repair (TCR), can be discerned. These
subpathways only differ in the first
damage recognition step. TCR elimi-
nates damage in actively transcribed
genes, whereas GGR removes DNA
damage throughout the remainder of the
genome. Unrepaired DNA damage may
lead to somatic mutations that have a role
in cancer induction and progression.
Because the clinical findings in XP are
associated with cellular defects, includ-
ing sensitivity of killing and mutagenic
effects of UV and the inability of XP
cells to repair UV-induced DNA
damage, XP provides a powerful model
for the study of melanoma in humans.
Multiple melanomas with the same
exposure history and genetic back-
ground can be studied in few patients
where the effects of UV damage are
amplified because of the NER defi-
ciency. For example, it was shown that
more than 90% of melanomas in XP
patients carried UV-type ‘‘fingerprint’’
mutations in the PTEN melanoma sup-
pressor gene (Wang et al., 2009).
This provides direct molecular
evidence of UV involvement in
melanoma disease in humans.
Markers for melanoma risk
The group of Dr Qingyi Wei (Li et al.,
2013) has studied molecular mela-
noma marker analysis for more than a
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decade. Originating from a laboratory
headed by late Dr Larry Grossman in
Baltimore, they started out assessing
functional cellular NER capacity mea-
sured in peripheral blood lymphocytes.
Such studies necessitate the establish-
ment of small-scale functional assays
due to the very limited lymphocyte cell
numbers available per patient. Wei and
others successfully applied host cell
reactivation for that purpose and in
2003 demonstrated that a reduced NER
activity is an independent risk factor for
the development of cutaneous mela-
noma in the general population (Wei
et al., 2003). Others have confirmed
these findings and showed that even a
slight reduction in DNA repair capacity
was associated with a significantly
increased cancer risk in patients with
lung cancer, head and neck squamous
cell cancer, or squamous cell carcino-
mas of the skin. The fact that defective
mechanisms for handling of UV-
induced DNA damage constitute a
melanoma risk marker was also demon-
strated in patients with dysplastic nevus
syndrome/familial melanoma. Their
lymphocytes exhibited spontaneous, as
well as post-UV, plasmid hypermuta-
bility using a shuttle vector assay (see
Blankenburg et al. (2005) and references
therein).
Markers for melanoma survival
Treatment efficacy and melanoma resis-
tance to certain chemotherapeutic regi-
mens may depend on DNA repair.
For example, applying functional assays,
it was shown that increased base
excision repair conferred resistance to
fotemustine and cisplatin in melanoma
cells in vitro and diminished mismatch
repair–conferred cellular fotemustine
and etoposide resistance. The efficacy
of the ‘‘standard’’ chemotherapeutic
treatment of metastasized melanoma
with dacarbazine or temozolomide
depends on low O-6-methylguanine-
DNA-methyltransferase repair and on
high mismatch repair.
More recently, the use of DNA repair
as an independent marker for melanoma
progression and disease survival has
come into focus. Gene expression pro-
files of primary cutaneous melanomas
associated with metastases to distant
sites and with poor prognosis revealed
DNA repair being among the most
significant pathways. Four out of
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Figure 1. The nucleotide excision repair (NER) pathway. In GGR, the XPC and XPE(DDB2) gene products recognize the DNA damage such as CPDs or
pyrimidine-6,4-pyrimidone photoproducts (6–4 PP) and initiate the NER cascade. In TCR in actively transcribed genes, the stalled RNA polymerase II in concert
with CSA(ERCC8) and CSB(ERCC6) gene products initiates the NER cascade. XPB(ERCC3) and XPD(ERCC2) gene products are components of the 10-subunit
multiprotein complex TFIIH (transcription factor II H) and demarcate the damage due to their helicase activity. These helicases along with the XPA and
XPG(ERCC5) gene products and replication protein A (RPA) unwind the DNA surrounding the lesion. The TTD-A(GTF2H5) gene product is also part of the TFIIH
complex. XPF(ERCC4) and XPG(ERCC5) gene products are endonucleases that cut the damage-containing DNA strand removing the lesion along with a fragment
of about 30 nucleotides. The resulting gap is filled using polymerases and ligases and the complementary DNA strand as a template. Mutations in the genes in
rectangles have been associated with clinical disease. Tag SNPs in XPC, XPE(DDB2), XPD(ERCC2), and XPG(ERCC5) genes (skulls) are associated with increased
risk of death from melanoma (see paper by Li et al., 2013). CPD, cyclobutane pyrimidine dimers; GGR, global genome repair; PCNA, proliferating cell nuclear
antigen; RF-C, replication factor C; SNP, single-nucleotide polymorphism; TCR, transcription-coupled repair; TTD-A, trichothiodystrophy A.
(Figure modified from DiGiovanna and Kraemer, 2012.)
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44 genes overexpressed in primary mela-
nomas with poor prognosis belonged to
the NER pathway (Kauffmann et al., 2008).
Single-nucleotide polymorphisms (SNPs)
and melanoma risk/survival
SNPs are variations in the DNA
sequence that are present in the normal
population, for example, replacing a
nucleotide C (cytosine) with a T
(thymine). There is about one SNP per
300 nucleotides with about 10 million
SNPs in the entire human genome.
The human genome has 23 pairs of
chromosomes. Each chromosome has
its own pattern of SNPs. The genotype
of the same SNP on each chromosome
of a pair is indicated by two letters, for
example, AG means ‘‘A’’ on one chro-
mosome (allele) and ‘‘G’’ on the other
chromosome of the pair.
Most SNPs are located between genes
and do not have known functions. How-
ever, some SNPs are located in or near
genes and can act as markers for inheri-
tance of a large group of nucleotides that
frequently appear together on the same
allele (haplotype). These marker SNPs
may be associated with differences in
drug responses, disease states, or cancer
risk. Genome-wide association studies
(GWASs) are a method to determine
possible associations of SNPs with a
disease. DNA from an affected group
and a control population is collected
and tested for the presence of a large
number of SNPs. A smaller number of
representative (tag) SNPs are often used
as markers of linked groups of SNPs.
SNPs in the XPC NER gene have been
shown by Dr Wei’s group to confer an
increased risk for melanoma develop-
ment (Li et al., 2006). SNPs in other
genes and pathways have also been
implicated in an increased melanoma
risk. These include the regulation of
skin pigmentation, such as the melano-
cortin-1 receptor gene, the production
of proteins of the steroid and thyroid
hormone superfamily, including vitamin
D and the peroxisome proliferator–
activated receptor genes, the detoxifica-
tion of oxidative stress metabolites, such
as the gluthation S-transferase genes, or
cytokine genes like the interleukin-10
gene. With modern high-throughput
techniques even more loci will most
likely be defined.
The paper by Li et al. (2013) is a
follow-up on their earlier GWAS on
SNPs and melanoma susceptibility in a
cohort of 1,804 melanoma cases and
1,026 controls (Amos et al., 2011). The
GWAS study examined about 1 million
SNPs and found increased melanoma
risk in association with loci on several
different chromosomes. They identified
novel chromosomal loci predisposing to
cutaneous melanoma including 15q13.1
(HERC2/OCA2 region), 16q24.3 (MC1R
region), 9p21.3 (p16/ARF region), and
1q21.3 (ARNT/LASS2/ANXA9 region).
The current paper examines survival
of 1,042 patients from this cohort after
3 years in relation to 74 tag SNPs
representing eight NER genes. They
found that four of the SNPs were asso-
ciated with reduced survival. Two of the
SNPs were rare—XPE AG genotype and
ERCC5/XPG AG genotype were
present in about 2% of the melanoma
patients. However, the other two SNPs
were much more common—XPC AA
genotype in 62.1% and ERCC2/XPD
AA genotype in 27.4%. The XPE and
ERCC5/XPG polymorphisms were asso-
ciated with 4- to 11-fold increased
hazard of early death, whereas the XPC
and ERCC2/XPD polymorphisms were
associated with about a doubling of risk
of death. The risk of death increased with
increasing numbers of these SNPs up to
34-fold if three of these adverse SNP
genotypes were present. The presence of
these variant SNPs was associated with
additional risk of death in melanoma
patients with unfavorable histopathologi-
cal risk factors such as increased tumor
thickness, involvement of lymph nodes,
increased mitotic rate, presence of
ulceration, and stage III or IV.
This is an intriguing exploratory study.
Although some of these results are
similar to several smaller studies of asso-
ciation of SNPs and melanoma survival,
they should be repeated with larger
cohorts with different genetic back-
grounds to determine the extent of
applicability of these findings. These
tag SNPs have not been reported as
having biological function and this can
be followed up. The rare genetic dis-
order, XP, has mutations in these same
NER genes resulting in greatly increased
melanoma risk. Molecular medicine
based on studies such as that reported
by Li et al. (2013) may soon be in clini-
cal use for melanoma risk assessment.
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Much Remains to Be Learned about
How UVR Induces Mutations
Thomas M. Ru¨nger1
Data on the wavelength dependence of UV-induced formation of DNA damage
and skin cancer have been available for quite some time, but a detailed in vivo
action spectrum of mutation formation has not yet been reported so far. This
important information gap is filled by Ikehata et al. in this issue. Their findings
question several aspects of our current thinking about UV-induced mutagenesis
and carcinogenesis.
Journal of Investigative Dermatology (2013) 133, 1717–1719. doi:10.1038/jid.2013.73
Photocarcinogenesis is a cascade of
events in which malignant transforma-
tion in a single cell results from
UV-induced DNA damage, with subse-
quent mutation formation. Tens of
thousands of mutations all over the
genome of a single cell are usually
required to yield a sufficient number
of mutations in critical genes. An
impressive example of how many muta-
tions do occur in skin cancer was pro-
vided by Pleasance et al. (2010): they
sequenced the whole genome of a
melanoma and found more than 33,000
mutations. The fact that more than
23,000 of those were C to T single-base
transition mutations (¼UV-signature
mutations) provides impressive mole-
cular evidence that most of this large
mutation load is the consequence of
lifelong sun exposure. This confirms
the current concept that UV-induced
pyrimidine dimer–type DNA damage
(cis-syn cyclobutane pyrimidine dimers
and pyrimidine (6-4) pyrimidone photo-
products) with subsequent formation of C
to T transition mutations at sites of this
type of DNA damage are major drivers
of photocarcinogenesis. However, many
details about the mechanisms involved
in mutation formation after UV exposure
have remained elusive.
UVR consists of a spectrum of wave-
lengths that have different photo-physical,
photo-chemical, and photo-biological
effects. UVR action spectra describe
changes in these effects with varying
wavelengths. Such action spectra have
been available for the formation of DNA
damage (Freeman et al., 1989; Kielbassa
et al., 1997; Young et al., 1998) and for
the formation of skin cancer (de Gruijl
et al., 1993) in various in vitro and in vivo
models. Except for data of mutation
formation in cultured fibroblasts with
five different wavelengths of UVA (315–
See related article on pg 1850
400 nm) and UVB (280–315nm; Enninga
et al., 1986), no action spectra for
mutation formation have been available
so far. In this issue, Ikehata et al. (2013)
describe a detailed action spectrum of
mutation formation in mice. They used
transgenic mice harboring the lacZ
mutagenesis target reporter gene and
studied the mutation formation separa-
tely in the dermis and in the epidermis,
following irradiation at 14 different
narrow-band wavelengths points, gene-
rated by a large high-intensity monochro-
mator or a 364-nm laser, ranging from
UVC to UVA1. The results close an
important gap in our knowledge about
UV-induced mutation formation and
carcinogenesis, as this is the first UVR
action spectrum of mutation formation
in vivo.
Is a severe sunburn more mutagenic and
carcinogenic than a mild sunburn?
In the epidermis, the authors observed
that mutation formation only increased
with increasing UVR doses until a
threshold dose was reached and then
leveled off. They termed this phenom-
enon as mutation induction suppression
(MIS), and the threshold dose as the
minimum mutation induction suppres-
sion dose (MMISD). It is apparently only
observed in vivo and not in cultured
cells. This is unlike the formation of
DNA damage by UVR that increases
with the dose of UVR and is not known
to level off. This new observation ques-
tions the concept that a higher dose of
UVR always results in more mutations.
There was a close correlation between
minimal erythema doses and the
MMISD. This indicates that a severe
sunburn may actually not produce more
mutations than a mild sunburn, and
therefore it may also not be more
carcinogenic than a mild sunburn.
Role of cellular or organism-based
damage responses on mutation formation
Many cellular defense mechanisms pre-
vent mutation formation at sites of DNA
damage, including DNA repair and cell
cycle arrest (to allow repair before replica-
tion of damaged DNA), so that a majority
of DNA lesions are actually repaired
before they cause mutations. The mechan-
ism by which mutation formation levels
off in vivo remains unclear, but Ikehata
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